Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.37 |
| ▸ | MYLK | Q15746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10967957 | 0.81 | LMNA (0.43) | LMNAALDH1A1PRKCEMYLKMEN1 | |
| SCHEMBL14048734 | 0.77 | DHFR (0.38) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5038760 | 0.74 | KDM4E (0.41) | LMNAALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL29638205 | 0.74 | KDM4E (0.41) | LMNAALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL29638209 | 0.74 | KDM4E (0.41) | LMNAALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL6218700 | 0.73 | AURKA (0.41) | — | |
| SCHEMBL30891087 | 0.72 | PDXK (0.31) | — | |
| SCHEMBL16796089 | 0.72 | PDXK (0.31) | — | |
| SCHEMBL27141621 | 0.72 | TYR (0.30) | — | |
| SCHEMBL6673049 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080101-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | PSMG3, PSMD2, PSME1 | LMNA 1706/4885ALDH1A1 2684/4885PRKCE 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.